{"nctId":"NCT00876694","briefTitle":"Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)","startDateStruct":{"date":"2009-03"},"conditions":["Chronic Obstructive Pulmonary Disease (COPD)"],"count":186,"armGroups":[{"label":"Indacaterol 300 µg","type":"EXPERIMENTAL","interventionNames":["Drug: Indacaterol 300 µg"]},{"label":"Salmeterol 50 µg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Salmeterol 50 µg"]}],"interventions":[{"name":"Indacaterol 300 µg","otherNames":[]},{"name":"Salmeterol 50 µg","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1\\. Diagnosis of COPD (moderate-to-severe as classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines) and:\n\n* Smoking history of at least 20 pack-years\n* Post-bronchodilator FEV1 \\<80% and ≥30% of the predicted normal value\n* Post-bronchodilator FEV1/FVC (forced vital capacity) \\<70%\n\nExclusion Criteria:\n\n1. Patients who have been hospitalized for a COPD exacerbation in the 6 weeks prior to Visit 1 or during the run-in period\n2. Patients who have had a respiratory tract infection within 6 weeks prior to Visit 1\n3. Patients with concomitant pulmonary disease\n4. Patients with a history of asthma\n5. Patients with diabetes Type I or uncontrolled diabetes Type II\n6. Any patient with lung cancer or a history of lung cancer\n7. Patients with a history of certain cardiovascular comorbid conditions\n8. Patients who have been exposed to indacaterol previously. (Except for any patient who enrolled in Study CQAB149B1302)\n\nOther protocol-defined inclusion/exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Number of Participants With a Clinically Notable Pulse Rate During 52 Weeks of Treatment","description":"The number of participants with newly occurring or worsening clinically notable vital sign: Pulse Rate in beats per minute (bpm) at anytime post baseline (BL) by treatment. Low Pulse Rate was defined as a pulse rate \\<40 bpm or \\<= to 50 bpm and a decrease from baseline \\>= to 15 bpm. High Pulse Rate was defined as a pulse rate \\>130 bpm or \\>= to 120 bpm and an increase from baseline \\>= to 15 bpm.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"The Number of Participants With a Clinically Notable Systolic Blood Pressure During 52 Weeks of Treatment","description":"The number of participants with newly occurring or worsening clinically notable vital sign: Systolic Blood Pressure (mmHg) at anytime post baseline (BL) by treatment.\n\nA Low Systolic Blood Pressure was defined as a systolic blood pressure measurement: \\<75 mmHg or \\<= to 90 mmHg and a decrease from baseline \\>= to 20 mmHg.\n\nA High Systolic Blood Pressure was defined as a systolic blood pressure measurement: \\>200 mmHg or \\>= to 180 mmHg and an increase from baseline \\>= to 20 mmHg.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"The Number of Participants With a Clinically Notable Diastolic Blood Pressure During 52 Weeks of Treatment","description":"The number of participants with newly occurring or worsening clinically notable vital sign: Diastolic blood pressure (mmHg) at anytime post baseline (BL) by treatment.\n\nA Low Diastolic Blood Pressure was defined as a diastolic blood pressure measurement: \\<40 mmHg or \\<= to 50 mmHg and a decrease from baseline \\>= to 15 mmHg.\n\nA High Diastolic Blood Pressure was defined as a diastolic blood pressure measurement: \\>115 mmHg or \\>= to 105 mmHg and an increase from baseline \\>= to 15 mmHg.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"The Number of Participants With a Clinically Notable QTc Interval Value During 52 Weeks of Treatment","description":"The number of participants with newly occurring or worsening clinically notable QTc Interval value at anytime post baseline.\n\nThe QTc interval is calculated using Fridericia's formula: QTc= QT/cube root RR. QTc is the interval between the Q and T waves corrected for heart rate and RR is the interval between two R waves in milliseconds (ms).\n\nNotable QTc interval \\>450 ms for males and \\>470 ms for females. The maximum QTc increase from baseline at any time during the study was also tabulated with absolute and relative frequencies for categories 30- 60 ms and \\>60 ms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Serum Potassium (mmol/L) at Weeks 4, 8, 12, 24, 36, 44, and 52","description":"The least squares mean of the serum potassium in mmol/L at weeks 4, 8, 12, 24, 36, 44 and 52. Mixed model used baseline serum potassium as a covariate.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.26","spread":"0.028"},{"groupId":"OG001","value":"4.28","spread":"0.039"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.30","spread":"0.032"},{"groupId":"OG001","value":"4.27","spread":"0.044"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.28","spread":"0.033"},{"groupId":"OG001","value":"4.35","spread":"0.044"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.34","spread":"0.035"},{"groupId":"OG001","value":"4.27","spread":"0.048"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.35","spread":"0.032"},{"groupId":"OG001","value":"4.29","spread":"0.044"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.31","spread":"0.033"},{"groupId":"OG001","value":"4.27","spread":"0.044"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.32","spread":"0.035"},{"groupId":"OG001","value":"4.31","spread":"0.048"}]}]}]},{"type":"PRIMARY","title":"Blood Glucose (mmol/L) 1 Hour Post Dose at Weeks 4, 8, 12, 24, 36, 44, and 52","description":"The least squares mean of the blood glucose in mmol/L at weeks 4, 8, 12, 24, 36, 44 and 52. Mixed model used baseline blood glucose as a covariate.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.10","spread":"0.187"},{"groupId":"OG001","value":"5.96","spread":"0.260"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.92","spread":"0.159"},{"groupId":"OG001","value":"6.30","spread":"0.220"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.97","spread":"0.199"},{"groupId":"OG001","value":"6.59","spread":"0.262"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.16","spread":"0.195"},{"groupId":"OG001","value":"6.13","spread":"0.271"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.95","spread":"0.137"},{"groupId":"OG001","value":"6.26","spread":"0.189"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.09","spread":"0.226"},{"groupId":"OG001","value":"6.42","spread":"0.309"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.96","spread":"0.220"},{"groupId":"OG001","value":"6.65","spread":"0.296"}]}]}]},{"type":"SECONDARY","title":"Trough Forced Expiratory Volume in 1 Second (FEV1) After 12, 24 and 52 Weeks","description":"Trough FEV1 was defined as the mean of the values at 23 h 10 min and 23 h 45 min after dosing at clinic on the previous day. Trough FEV1 was analyzed after 12, 24 and 52 weeks using a mixed model which contained the baseline FEV1 measurement, FEV1 prior to inhalation and FEV1 30 minutes post inhalation of salbutamol as covariates.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.40","spread":"0.013"},{"groupId":"OG001","value":"1.33","spread":"0.019"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.40","spread":"0.016"},{"groupId":"OG001","value":"1.34","spread":"0.022"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.39","spread":"0.017"},{"groupId":"OG001","value":"1.31","spread":"0.023"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":16,"n":125},"commonTop":["Nasopharyngitis","Chronic obstructive pulmonary disease","Cough","Upper respiratory tract infection","Bronchitis"]}}}